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All tauopathies, including Alzheimer’s disease (AD), are characterized by the intracellular
accumulation of abnormal forms of tau protein in neurons and glial cells, which
negatively affect microtubule stability. Under physiological conditions, tubulin-associated
unit (Tau) protein is intrinsically disordered, almost without secondary structure, and
is not prone to aggregation. In AD, it assembles, and forms paired helical filaments
(PHFs) that further build-up neurofibrillary tangles (NFTs). Aggregates are composed of
hyperphosphorylated tau protein that is more prone to aggregation. The pathology of
AD is also linked to disturbed copper homeostasis, which promotes oxidative stress
(OS). Copper imbalance is widely observed in AD patients. Deregulated copper ions
may initiate and exacerbate tau hyperphosphorylation and formation of β-sheet-rich tau
fibrils that ultimately contribute to synaptic failure, neuronal death, and cognitive decline
observed in AD patients. The present review summarizes factors affecting the process of
tau aggregation, conformational changes of small peptide sequences in the microtubule-
binding domain required for these motifs to act as seeding sites in aggregation, and the
role of copper in OS induction, tau hyperphosphorylation and tau assembly. A better
understanding of the various factors that affect tau aggregation under OS conditions
may reveal new targets and novel pharmacological approaches for the therapy of AD.
Keywords: copper, tau, aggregation, oxidative stress, Alzheimer’s disease
INTRODUCTION
Tubulin-associated unit (Tau) is a microtubule-associated phosphoprotein predominantly
expressed in neuronal cells, mainly in axons. It is essential for proper assembly, stabilization,
and functioning of a microtubule network. Tau also regulates axonal transport, drives neurite
outgrowth, and shapes the neuronal morphology (Choi et al., 2009; Wang and Mandelkow, 2016).
Abbreviations: AD, Alzheimer’s disease; Aβ, amyloid-β peptides; cdk5, cyclin-dependent kinase 5; ERK1/2, extracellular
signal regulated kinase-1/2; GSK-3β, glycogen synthase kinase-3β; I2PP2A, inhibitor-2 of protein phosphatase-2A; MAP,
microtubule-associated protein; MAPKs, mitogen activated protein kinases; NFT, neurofibrillary tangles; OS, oxidative
stress; PHF, paired helical filaments; PP2A, protein phosphatase 2A; ROS, reactive oxygen species; RNS, reactive
nitrogen species.
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Human tau is a relatively large protein with six isoforms
derived from a single gene. The isoforms range in length from
352 to 441 amino acids. Tau is divided into two functional
domains: a projection domain at the N-terminus, and a
microtubule-binding domain at the C-terminal part (for review,
see Šimi ć et al., 2016; Barbier et al., 2019). Regarding tau-related
pathology, the major difference between the isoforms is located
in the microtubule-binding domain that contains three or
four imperfect pseudorepeat units (R1–R4). Each repeat consists
of a 31–32 amino acid sequence that contains a highly conserved
fragment of 18 residues (octadecapeptide). Accordingly, the
isoforms are termed as either 3R-tau or 4R-tau isoforms. They
all encompass the third repeat R3 (residues 306–336 according
to the longest human tau isoform) and differ from each other by
the absence or presence of the R2 repeat. The 4R-tau isoforms
bind to microtubules with higher affinity. In the healthy human
brain, 3R-/4R-tau isoforms are expressed in a similar ratio, but
this ratio is disturbed in Alzheimer’s disease (AD; for review, see
Alavi Naini and Soussi-Yanicostas, 2015; Liu et al., 2015; Cheng
and Bai, 2018). The other difference between the isoforms is the
number of N-terminal inserts in the projection domain (0N, 1N,
or 2N). A proline-rich region flanking the microtubule-binding
domain and the projection domain facilitates tau interaction with
microtubules. The N-terminal part of tau determines the spacing
between microtubules and does not participate in microtubule
binding (Schneider et al., 1999; Kadavath et al., 2015; Cheng and
Bai, 2018; Barbier et al., 2019).
Tau binds tightly to microtubules with the small groups of
evolutionarily conserved residues, whereas intervening parts stay
flexible. Thus, tau remains highly dynamic despite being bound
to microtubules. These small groups of microtubule-binding
motifs stabilize protofilament conformation of microtubules
by binding to a hydrophobic pocket at the interface between
α-β-tubulin heterodimers. The mechanism is similar for 3R-tau
or 4R-tau isoforms. The residues participating in binding
to microtubules are critically involved in tau aggregation, a
hallmark feature of AD (Kadavath et al., 2015).
EFFECT OF TAU PHOSPHORYLATION AND
TAU KINASES ON TAU FUNCTION
Tau is susceptible to many posttranslational modifications that
modulate its function and contribute to the heterogeneity of
tau isoforms present in the brain. The diversity of biological
tau functions is mainly regulated by phosphorylation that
attracted much attention as a modification particularly relevant
for the propagation of AD pathology (Jazvinšs ćak Jembrek et al.,
2013; Alavi Naini and Soussi-Yanicostas, 2015; Šimi ć et al.,
2016; Barbier et al., 2019; Miao et al., 2019). In AD tau
is hyperphosphorylated and is not attached to microtubules.
Hyperphosphorylation, represented as an overall increase of
phosphorylation at multiple residues, reduces the binding
affinity of tau for microtubules and is responsible for the
loss of the physiological tau functions. Hyperphosphorylation
disturbs interactions between tau and microtubules and results
in microtubule instability, decreased microtubule bundling,
impairment of axonal transport and neuronal architecture, and
ultimately cell death (Evans et al., 2000; Alavi Naini and Soussi-
Yanicostas, 2015; Barbier et al., 2019).
Besides interacting with microtubules, tau at its N-terminal
part may bind signaling proteins that contain Src homology
3 (SH3) domains, including the non-receptor tyrosine kinase
Fyn. Fyn is elevated in the AD brain, particularly in neurons
with hyperphosphorylated tau, and contributes to the increase
in tau levels by promoting tau translation. Fyn itself also
may phosphorylate tau at Tyr18, and this phosphorylation
step has been linked to AD pathology (Lee et al., 2004).
However, the most prominent role of Fyn in AD is related
to the effects of tau on Aβ toxicity. It is considered that the
mislocalization of phosphorylated tau from the axons into the
dendritic compartments mediates the toxic effects of Aβ by
locally increasing concentration of Fyn (Li and Götz, 2017;
Nygaard, 2018). In physiological conditions, tau is present in low
amounts in dendrites but has an important role in sequestering
Fyn to postsynaptic dendritic membranes where Fyn strengthens
interactions between NMDA receptors containing NR2B subunit
and postsynaptic density (PSD) protein PSD-95. This is crucial
in AD for driving excitotoxic signaling cascade triggered by
soluble Aβ oligomers (Alavi Naini and Soussi-Yanicostas, 2015;
Nygaard, 2018).
The longest tau isoform possesses 85 residues that can be
phosphorylated. Almost 45 of them are phosphorylated in the
AD brain, in comparison to 10–18 from the healthy adult
human brain. Very few of the phosphorylated residues occur
in the N-terminal region and the microtubule-binding domain.
Instead, phosphorylation sites are mainly located in the flanking
regions of the microtubule-binding domain (for review, see
Alavi Naini and Soussi-Yanicostas, 2015; Wang and Mandelkow,
2016). Tau phosphorylation is mediated by many kinases, at
least in vitro. Among them, glycogen synthase kinase-3β (GSK-
3β) and cyclin-dependent kinase 5 (cdk5) are considered as
particularly important. Increased activity of GSK-3β, as well
as upregulation of cdk5 and its activators, p35, and p25, were
found in the frontal cortex of AD brain samples (Duka et al.,
2013). These kinases phosphorylate tau at multiple serine and
threonine residues known to be implicated in AD, and their
overexpression or activation induces tauopathy-characteristic
phenotypes (Terwel et al., 2008; Kremer et al., 2011; Jazvinšs ćak
Jembrek et al., 2013; Llorens-Martín et al., 2014). GSK-3β
truncated at the C-terminus is markedly increased in the AD
brain, and truncation shows a positive correlation with tau
hyperphosphorylation and Braak stage. Proteolytic cleavage of
GSK-3β by calpain I increase its kinase activity (Feng et al., 2013;
Jin et al., 2015). Both kinases are hyperactivated in oxidative
stress (OS)-conditions (Shukla et al., 2012; Alavi Naini and
Soussi-Yanicostas, 2015), suggesting that attenuation of ROS
generation might reduce their activity and alleviate the level of
tau hyperphosphorylation.
TAU AGGREGATION IN AD AND OTHER
TAUOPATHIES
Besides destabilizing microtubules, hyperphosphorylated
tau forms intraneuronal deposits upon detachment from
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microtubules. This is somewhat unexpected due to the very high
solubility of tau (Schneider et al., 1999). In a self-propagating
aggregation process, tau at first forms dimers and then oligomers
that accumulate to form protomers. Pairs of protomers twist
around each other and generate paired helical filaments (PHFs)
that associate and grow into bundles of neurofibrillary tangles
(NFTs; for review, see Mokhtar et al., 2013; Liu et al., 2015).
As fetal tau isoform (0N3R) does not form PHF even in a
highly phosphorylated state, understanding its expression
and post-translational modifications may be important for
future research towards the development of AD treatment and
prevention (Jovanov-Milošsevi ć et al., 2012).
In addition to hyperphosphorylation, cleavage of tau
by various proteases (such as caspases and calpains), is
another modification important for the etiopathogenesis of AD
(Kovacech and Novak, 2010; Zhou et al., 2018). Tau cleavage
generates tau fragments that span the pseudorepeats of the
microtubule-binding domain and are C-terminally truncated at
Glu391. These truncated fragments build the structural core
of PHFs. Tau fragments from the core are made of C-shaped
units and are exactly three repeats in length, independent of
originating from 3R- or 4R-tau isoforms (Wischik et al., 2014,
2018). Thus, the fibril core of PHFs, which is proteolytically
resistant, is built by only a small part of tau, the repeat sequences.
It is surrounded by a highly dynamic fuzzy coat originating
from the residues from the C- and N-termini, whereas a
network of intramolecular long-range electrostatic interactions
links the core with this fuzzy coat (Bibow et al., 2011). Related
to AD progression, truncated tau must be capable of seeding
tau aggregation by triggering the conversion of full-length tau
into truncated form (Wischik et al., 2014, 2018; Fitzpatrick
et al., 2017). Asparagine endopeptidase, a cysteine proteinase-
activated during aging and in AD, acts as an important mediator
of neuropathological tau changes. It degrades tau, impairs its
function in microtubule assembly, and promotes aggregation
(Zhang et al., 2014b).
The whole tau protein has a low ability to aggregate
in vitro, although fragments containing pseudorepeat units
assemble much more readily based on their ability to form
intermolecular disulfide bridges (Schweers et al., 1995). A
prerequisite for nucleation is the formation of dimers (Friedhoff
et al., 1998). Hence, in experimental conditions, PHF assembly
is often promoted through the dimerization via disulfide
bond formation and in the presence of polyanions (such as
heparin) and inhibited in the presence of reducing agents
that keep cysteine residues reduced, preventing the dimer
formation (von Bergen et al., 2000). As for other amyloids,
it is considered that β-sheet conformation is critical for the
aggregation and fibril formation, although both α-helices and
β-sheet structures are found in PHFs (Sadqi et al., 2002;
Ma et al., 2005). However, amyloid structures are challenging
for characterization as they are not entirely ordered, which
complicates the precise determination of the structure-pathology
relationship (Fichou et al., 2019). Nevertheless, tau aggregates
appear before amyloid β (Aβ) plaques in AD, and their
accumulation correlates better with the severity of AD pathology
and cognitive decline than the formation of Aβ deposits
(Bussière et al., 2002; Wischik et al., 2014; Šimi ć et al.,
2017). As many years of research efforts along the Aβ cascade
hypothesis did not bring improvements in AD therapy, targeting
tau pathology is attracting much attention in recent days
(Šimi ć et al., 2016; Cheng and Bai, 2018; Jadhav et al., 2019;
Takeda, 2019).
The impact of other posttranslational modifications on
tau function and aggregation is much less characterized. In
contrast to normal tau that does not contain glycans, PHF
tangles from AD brains are highly glycosylated. However,
deglycosylation alone is not sufficient for tau to regain
microtubule polymerization capacity, both deglycosylation and
dephosphorylation are required for promoting microtubule
assembly. After deglycosylation, PHFs are converted into bundles
of straight filaments indicating a role of glycosylation in
PHF formation (Wang et al., 1996; Takahashi et al., 1997).
Another important posttranslational modification that may
regulate tau function is acetylation at lysine residues. Similar to
phosphorylation, acetylation inhibits tau function in microtubule
assembly by impairing interaction with microtubules and
promotes the formation of tau fibrils. Lys280 from the
microtubule-binding domain is considered to be one of the major
sites of tau acetylation. In brain tissue of Tg mouse models and
in extracted PHFs form cortical regions of various human 4R or
3R/4R tauopathies, increased levels of acetylation, specifically at
Lys274 and Lys280, were observed in pathologically insoluble,
hyperphosphorylated tau aggregates (Cohen et al., 2011; Alavi
Naini and Soussi-Yanicostas, 2015). A better understanding of
the contribution of other post-translational tau modifications on
tau pathology, particularly during OS, might bring some novel
opportunities in AD treatment.
The human brain is neither susceptible only to neuronal
tau accumulation nor are tau aggregates specific for AD.
Besides, aging itself leads to the build-up of tau tangles,
primarily in the medial temporal lobe, which is known as
primary age-related tauopathy (Crary et al., 2014; Huang
et al., 2016; Demaegd et al., 2018). In more than 30 different
forms of tauopathies, inclusions of hyperphosphorylated tau
with various morphological appearances can be found in
neurons, astrocytes, and oligodendrocytes (Alavi Naini and
Soussi-Yanicostas, 2015; Kahlson and Colodner, 2016). Of
note, tau is normally expressed in glial cells, particularly
in oligodendrocytes, although at a much lower level in
comparison to neurons. The list of tauopathies includes,
but is not limited to, frontotemporal dementia, progressive
supranuclear palsy, corticobasal degeneration, argyrophilic grain
disease, Gerstmann–Sträussler–Scheinker disease, white-matter
tauopathy with globular glial inclusions, as well as several other
forms of dementia. At the molecular level, a distinction between
different tauopathies is based on phosphorylation, and the
number of tau isoforms displayed in aggregates (for review, see
Alavi Naini and Soussi-Yanicostas, 2015). For example, in AD all
six tau isoforms are found in aggregates.
The contribution of glial tau pathology to the pathogenesis of
tauopathies is not well understood, although at least theoretically,
its targeting may bring some therapeutic hope for AD. Namely, it
is considered that tau pathology in glial cells disrupts the normal
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 September 2020 | Volume 13 | Article 572308
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role of glia in supporting neuronal functioning. These include
the role of astrocytes in maintaining the blood-brain barrier
and modulation of synaptic function, particularly through the
secretion and uptake of glutamate, as well as the myelinating
function of oligodendrocytes (for review, see Kahlson and
Colodner, 2016; Leyns and Holtzman, 2017).
TAU SPREADING
The progressive nature of AD is largely based on the spreading
of misfolded tau through synaptically interconnected neural
pathways. As such, extracellular tau enters cells and then
triggers the formation of tau fibrils from the intracellular
tau pool. The small and soluble oligomeric tau forms are
considered as the most pathogenic and transmissible moieties.
Hence, the inhibition of oligomer formation and clearance of
oligomeric forms of low molecular weight could represent a
valuable therapeutic approach (Fichou et al., 2019). However,
a prerequisite for this is understanding the aggregation process
and identification of various AD-related biological factors and
components of the intracellular environment that may affect
its dynamic.
Small oligomers and prefibrillar species enable propagation
of tau pathology through a cell-to-cell transmission manner
(Lasagna-Reeves et al., 2012; Alavi Naini and Soussi-Yanicostas,
2015; Wang and Mandelkow, 2016) or via microglial cells
(Špani ć et al., 2019). Tau enters at both somatodendritic
and axonal compartments and proceeds anterogradely
and retrogradely, thus spreading both trans-synaptically
and transcellularly (Demaegd et al., 2018). The two major
components of the propagation process are a templated
misfolding or ‘‘seeding’’ (i.e., the ability of abnormal tau to
induce a conformational change of the naturally folded tau
protein) and cell-to-cell spreading (Demaegd et al., 2018).
It is likely that tau propagates cell-to-cell through tunneling
nanotubes (filamentous channels) or is released into the
extracellular space in a free form or through transport vesicles
by various secretion mechanisms, and is then subsequently
taken up by nearby cells (Demaegd et al., 2018). However, a
more recent epidemic spreading model predicts the spreading
of tau from cell to cell only through neuronal projections, not
the extracellular space (Vogel et al., 2020). Tau also spreads
ubiquitously through the communication pathways during
normal aging, particularly in the medial temporal cortex. In
AD, the process is facilitated in regions with Aβ-burden and
results in the spreading of tau outside from the medial temporal
lobes into the nearby neocortex, in a good correlation with the
level of neurodegeneration and cognitive impairment. NFTs are
first formed in the brainstem and transentorhinal cortex from
where they outspread to the anterior hippocampus, temporal
association neocortex, and ultimately primary sensory cortex
through secondary seeding events (Šimi ć et al., 1998, 2009;
Vogel et al., 2020).
There is evidence in support of cell-to-cell tau spreading,
a phenomenon that is hard to prove by examining the
post-mortem human brain. In non-neuronal cells overexpressing
tau, hyperphosphorylation accompanied by caspase-3-mediated
cleavage at Asp421 promoted extracellular excretion of tau
(Plouffe et al., 2012). A spread of pathological tau in a cell
type-specific manner was demonstrated after the intracerebral
injection of AD brain extract enriched in pathological tau
into the hippocampus and overlying cortex of human mutant
P301S tau transgenic mice (PS19 mice; Boluda et al., 2015).
Similarly, injection of oligomeric and hyperphosphorylated tau
from AD brain (AD P-tau) into the hippocampus of human tau
transgenic mice resulted in tau aggregation pathology, as well
as tau hyperphosphorylation, in the contralateral hippocampus
and ipsilateral cortex (Miao et al., 2019). Injection of brain lysate
containing tau aggregates into the normal brain or the brain
of young transgenic mice may result in severe tau pathology at
the injection site, and in anatomically connected regions (Leyns
and Holtzman, 2017), suggesting that misfolded tau protein
propagates to neighboring cells along synaptically connected
circuits spatially and temporally (Lasagna-Reeves et al., 2012; Liu
et al., 2012).
By searching for the minimal sequence capable of defining the
self-propagating process, it was found that a peptide spanning the
full R3 repeat may form amyloid fibril and in a self-propagating
manner, induce misfolding of the microtubule-binding domain
and spread the disease (Stöhr et al., 2017).
CONFORMATIONAL CHANGES REQUIRED
FOR TAU POLYMERIZATION
It is generally accepted that tau hyperphosphorylation promotes
detachment from microtubules and its polymerization and
aggregation. PHFs can be formed from the fragments of tau
protein that lack a majority of the phosphorylation sites (Wille
et al., 1992). Also, PHFs isolated without protease digestion
are labeled by antibodies directed against phosphorylated
epitopes in the N-terminal part of tau, but after removal of
a fuzzy coat, the immunoreactivity is lost. This indicates that
a fuzzy coat contains most of the amino acid residues that
are phosphorylated (Šimi ć et al., 2016; Wischik et al., 2018).
Moreover, tau phosphorylation at specific phosphorylation
sites may antagonize PHF formation. Thus, phosphorylation
at Ser214 and Ser262 prevents tau binding to microtubules
and PHFs assembly, suggesting that phosphorylation has a
protective role by preventing tau aggregation (Schneider et al.,
1999). In another study, the formation of NFTs was associated
with reduced oxidative damage, leading to the conclusion
that tau phosphorylation could have an antioxidative function,
serving as a response intended to maximally protect neuronal
structure and function against oxidative injury (Smith et al.,
2002; Su et al., 2010). As the self-assembling of the constructs
corresponding to the repeat region occurs after the formation
of cross-linked dimers, it is suggested that an increase in
neuronal redox potential and excessive protein oxidation are
mainly responsible for PHFs formation (Wille et al., 1992;
Schweers et al., 1995).
Therefore, at the root of tau oligomerization are
conformational changes that make tau more prone to
aggregation. The aggregation is initiated at the nucleation
sites through the local transition from a random coil to a
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 September 2020 | Volume 13 | Article 572308
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β-sheet structure. As mentioned, dimerization via disulfide bond
formation (cross-linking) is essential for nucleation, but many
conformational and structural rearrangements are required for
the transition from dimers and early oligomeric forms to mature
fibrils (Friedhoff et al., 1998; von Bergen et al., 2005; Ganguly
et al., 2015). Both α-helices and β-sheet structures are found in
ex vivo PHFs (Ma et al., 2005). Some conformational changes
may be induced by tau phosphorylation, although, as already
mentioned, low phosphorylated tau is also able to polymerize.
Hence, it is hypothesized that some other mechanisms,
such as OS, act synergistically with phosphorylation, and
induce conformational changes required for PHF assembly
(Pérez et al., 2000).
THE ROLE OF HEXAPEPTIDE MOTIFS IN
TAU AGGREGATION
The PHF core being predominantly built from the repeat
domains (Tomoo et al., 2005; von Bergen et al., 2005; Wischik
et al., 2018), the microtubule-binding domain plays an important
role in tau aggregation. The R3 repeat unit present in all tau
isoforms contains the sequence that may act as the nucleation
core critical for the initiation of tau oligomerization (von
Bergen et al., 2000; Ganguly et al., 2015; Stöhr et al., 2017).
Identification of the smallest tau elements capable of nucleation
is important as could represent conformational targets for
therapeutic interventions by specifically designed inhibitors
aimed to prevent tau aggregation. von Bergen et al. (2000) have
identified a fragment containing R3 repeat plus some residues
from the flanking region as the shortest peptide sequence with
a secondary structure element capable to initiate tau aggregation
into PHFs. The fragment originated from the fetal tau isoform
and was named PHF43. PHF43 self-assembles quickly into
the straight thin filaments. Although the periodic supertwist
characteristic for PHFs found in AD was absent from the
filaments formed, seeds derived from these fibers nucleated
the formation of PHFs from the larger tau fragments and
the full-length tau. PHFs assembly was accompanied by an
increase in the β-structure content (von Bergen et al., 2000).
Within PHF43, based on the highest potential for β-structure
formation, a hexapeptide 306VQIVYK311 (PHF6) was identified
as a minimal interaction motif that underlies interactions
between tau or tau-derived fragments. The R2 repeat contains
a similar nucleating motif (PHF6*, 275VQIINK280) that also
includes residues with a high propensity for β conformation,
but is present only in isoforms with four repeats (von Bergen
et al., 2001). Other studies confirmed the critical involvement
of PHF6 or PHF6* motifs in mediating intermolecular
interactions between tau molecules and the formation of tau
oligomers, suggesting that two small hexapeptide motifs are both
essential and sufficient for polymerization (Goux et al., 2004;
Peterson et al., 2008).
PHF ASSEMBLY
PHF assembly is probably triggered by these hexapeptide
fragments that locally form β-structure embedded in a
random-coil structure of the whole protein. Dimerization at
cysteine residues may bring hexapeptide motifs into close
vicinity, facilitating interactions between β-sheets (von Bergen
et al., 2000). Accordingly, mutation of cysteine residues in the
R3 sequence changed amyloid morphology and their physical
properties and reduced seeding ability (Stöhr et al., 2017).
Similarly, if any residue from the PHF6 or PHF6* were replaced
with proline, which is a β-sheet disrupting residue, the ability of
polymerization would be prevented (von Bergen et al., 2001). von
Bergen et al. (2000) also reported that only a small part of the
entire protein, with a high β-sheet-forming propensity, serves as
a seed for assembly, whereas C- and N-terminal tails protrude
from the ordered core forming a fuzzy coat. However, further
studies have revealed that in addition to PHF6 and PHF6*, other
tau-originating peptides from the microtubule-binding domain
and with the high amyloidogenic predispositions, also may act
as primary nucleating sequences and promote the formation
of various amyloids, such as filaments, tubes, ribbons or rolled
sheets (Moore et al., 2011).
In larger tau fragments, PHF6 and PHF6* may interact with
each other and with themselves, generating a heterogeneous
mixture of oligomeric species as a result of intermolecular
interactions (PHF6-PHF6, PHF6-PHF6* and PHF*-PHF*;
Peterson et al., 2008; Ganguly et al., 2015). Nevertheless, a
small peptide fragment containing PHF6 (R3/wt) exhibited a
higher propensity for aggregation than fragment containing
PHF6*(R2/wt), and R3/wt assembly was delayed in the presence
of R2/wt (Ganguly et al., 2015). R3/wt peptide preferentially
formed homodimers, although stable R3/wt-R2/wt heterodimers
were also present and were more stable than R2/wt homodimers.
Individual chains within the R3/wt homodimers preferred a
parallel orientation, whereas dimers consisting of R2/wt peptides
adopted an antiparallel conformation that is in general indicative
of a slower aggregation kinetics. In parallel alignment, it is
easier for β-sheets to form a steric zipper that is critical for the
formation of fibrillary aggregates. Besides, multiple hydrogen
bonds were formed between the R3/wt peptides in more than
95% of all dimers formed, and they conferred to the stability
of dimers. For comparison, in R2/wt dimers, only 10–20% of
them had four or more hydrogen bonds (Figure 1). Taken
together, it was concluded that the role of PHF6 as a seed
that drives tau aggregation seems dominant over the role of
PHF6* (Ganguly et al., 2015). However, inhibitors based on the
structure of PHF6 were not effective in preventing seeding by
full-length tau, and a recent study suggested that PHF6* could
be the more potent initiator of tau aggregation and seeding
(Seidler et al., 2018).
Nevertheless, further studies have questioned whether
hexapeptide sequences alone represent the self-propagating
core, and continued the search for the minimal fragment
capable of inducing template misfolding and aggregation. It was
found that PHF6 formed amyloids very rapidly, but gradual
elongation in five-residue steps to the full length of the R3 repeat
slowed down the amyloid formation and markedly altered fiber
morphology (Stöhr et al., 2017). More importantly, by studying
externally induced aggregation of the endogenously expressed
tau244–372 fragment with the disease-associated mutations
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FIGURE 1 | Role of hexapeptide motifs PHF6 and PHF6* in tau dimerization. Residues from the microtubule-binding domain are critically involved in tau
aggregation. Studies in vitro have revealed that the nucleating sites from the R2 (PHF6*) and R3 (PHF6) repeat units seed tau aggregation. The PHF6 motif is a
predominant trigger of tau dimerization based on its intrinsically higher propensity for aggregation, higher stability due to hydrogen bonding, and parallel orientation of
peptide sequences in dimers. The positions of amino acid residues forming the paired helical filaments (PHFs) core are indicated according to Wischik et al. (2018).
P301L/V337M [named tau-RD(LM)], a large difference of
these growing-in-length peptides was observed in their ability
to induce aggregation. Amyloids formed from the 31-residue
long R3 sequence were as effective as fibrillized tau-RD in
inducing tau-RD(LM) aggregation. On the contrary, PHF6 and
growing peptides shorter than 20 residues, were not able to
seed aggregation of tau-RD(LM). Thus, in extension from
hexapeptide to peptide containing 31 residues, the resulting
peptides formed amyloids more slowly but at the same time were
more potent to induce template misfolding (Stöhr et al., 2017).
Despite the great efforts that have been put in untangling the
process of tau aggregation in vitro, there are still many open
questions. It must be taken in mind that these experiments were
performed on arbitrary tau fragments, largely in the absence of
post-translational modifications. Hence, it is still not clear if the
arrangement of recombinant filaments resembles those present
in a real biological system, where many factors may affect tau
assembly, particularly in the diseased brain (Fichou et al., 2019).
To understand the assembling process in vivo better, cryoelectron
microscopy has been employed for monitoring PHFs and straight
filaments from the AD brain. The analysis revealed that they
consist of hyperphosphorylated, full-length tau and can nucleate
aggregation of human full-length tau in cultured cells. Even
though in vitro studies demonstrated higher propensity of R2 and
R3 pseudorepeats for aggregation, the ordered core of both
types of filaments obtained from AD brain was made of pairs
of identical protofilaments containing C-shaped subunits from
residues 306 to 378, encompassing the entire R3 and R4 repeat
units plus 10 residues following, while N- and C-termini formed
disordered fuzzy coat as already explained (Fitzpatrick et al.,
2017). Importantly, it seems that the structures of tau filaments
are similar among AD patients indicating a common pattern
of tau folding (Falcon et al., 2018). Hence, further studies
must be directed towards a better understanding of molecular
mechanisms of tauopathies by examining tau filaments from
the AD brain, which hopefully will improve diagnostics and
accelerate the development of disease-modifying therapies.
OXIDATIVE STRESS AND TAU
AGGREGATION
OS includes conditions in which an increase in the level of
reactive oxygen and nitrogen species (ROS and RNS) surpasses
the endogenous mechanisms of antioxidant defense provided
by various enzymatic and non-enzymatic antioxidants. Through
the increased formation of ROS and RNS, OS induces oxidative
damage of essential macromolecules that threatens neuronal
structure and ultimately function (Nunomura et al., 2001; Alavi
Naini and Soussi-Yanicostas, 2015; Jazvinšs ćak Jembrek et al.,
2015; Liu et al., 2015, 2017).
When compared to other cell types, neurons are
particularly sensitive to OS and ROS- and RNS-mediated
injury (Cobley et al., 2018; Wang et al., 2020). Many lines
of evidence indicate that OS is an important early event in
the pathogenesis of AD neurodegeneration (Nunomura et al.,
2001; Mondragón-Rodríguez et al., 2013; Alavi Naini and
Soussi-Yanicostas, 2015; Liu et al., 2015, 2017; Wang et al.,
2020; Yeung et al., 2020). Acute OS may differentially affect
tau phosphorylation, but chronic exposure to OS promotes
tau hyperphosphorylation and makes tau more prone to
oligomerization and formation of NFTs (Patil and Chan, 2005;
Su et al., 2010; Mondragón-Rodríguez et al., 2013; Liu et al., 2015;
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Jazvinšs ćak Jembrek et al., 2018). Thus, prolonged OS
induced by sub-lethal inhibition of glutathione synthesis
increased phosphorylation at PHF-1 epitope in differentiated
M17 neuroblastoma cells, probably due to increased activity of
kinases JNK and p38 and reduced activity of protein phosphatase
2A (PP2A). Of note, activation of JNK and p38 was observed
in vivo, together with colocalization to NFTs (Su et al., 2010).
As the phosphorylation at the PHF-1 site is required for the
formation of tau filaments, these results are also indicative of
tau aggregation that was confirmed by the presence of high
molecular weight bands (Su et al., 2010). Based on these findings
it is suggested that OS precedes tau hyperphosphorylation and
aggregation (Figure 2). In HT22 neuronal cells, OS alone was
not capable to increase tau phosphorylation but changed the
pattern of tau phosphorylation. When OS was combined with the
inhibition of phosphatase activity, tau was highly phosphorylated
and also a poor substrate for proteasomal degradation, indicating
that both oxidation and hyperphosphorylation of tau are
important for tau aggregation (Poppek et al., 2006).
Acrolein, a peroxidation product from arachidonic
acid that is increased in the AD brain, also promotes
tau hyperphosphorylation by activating GSK-3β and p38,
emphasizing again an important role of OS and lipid
peroxidation in tau phosphorylation (Gómez-Ramos et al.,
2003). 4-hydroxy-2-nonenal (HNE), an end-product of
lipid peroxidation, increased the assembling capacity of
phosphorylated 4R-tau (Pérez et al., 2000). Phosphorylated tau
was more vulnerable to conformational changes in reaction
with HNE that further accelerated its polymerization and
formation of NFTs, suggesting an important role of HNE
in NFTs formation (Liu et al., 2005). Hence, possibly the
oxidation of fatty acids could be a prerequisite for promoting
tau hyperphosphorylation, serving as a link between OS and
tau filament formation (Gamblin et al., 2000). Interestingly,
neuronal exposure to stearic and palmitic fatty acids does
not increase tau phosphorylation. Instead, conditioned media
from astrocytes treated with saturated fatty acids increased tau
phosphorylation at AD-specific sites. As the effect was reduced
by treatment with an antioxidant, it was concluded that astroglia-
mediated OS significantly contributes to tau phosphorylation
(Patil and Chan, 2005).
TAU IN AN OXIDATIVE ENVIRONMENT
Tau is susceptible to OS and OS is considered as an important
factor contributing to NFT formation (for review, see Liu
et al., 2015). NFTs are identified as sites of catalytic redox
reactivity in the hippocampal tissue of AD patients (Sayre
et al., 2000). Accumulation of hyperphosphorylated tau
species stimulates the production of ROS and induction
of OS conditions, but OS in turn directly promotes tau
hyperphosphorylation. In this vicious cycle levels of both ROS
and abnormal tau increase progressively, ultimately leading
to neuronal death (Alavi Naini and Soussi-Yanicostas, 2015).
Moreover, OS-mediated abnormal tau phosphorylation is
likely a critical deregulator of physiological tau function at the
synaptic terminals and an important underlying mechanism
of a synaptic failure, in addition to its role in Fyn-mediated
and Aβ-driven synaptotoxicity via excitotoxic pathways
(Mondragón-Rodríguez et al., 2013).
Besides affecting tau function, OS also modulates the
expression and activity of enzymes that are involved in tau
phosphorylation. In neuronally differentiated PC12 cells exposed
to H2O2, low concentrations of GSK-3β inhibitor offered
protection against OS, whereas higher concentrations exhibited
the opposite effect (Lee et al., 2007). 1,2-diacetylbenzene, a
neurotoxic metabolite of an organic solvent 1,2-diethyl benzene,
also promoted the production of ROS, stimulated the activity
of GSK-3β, and increased phosphorylation of tau in the
hippocampus of male C57BL/6 mice (Kang et al., 2017). In
the hippocampus and cortex from the AD human brain,
activation and distribution of p38 kinase, which is known to
be induced by OS, exclusively colocalized with the intracellular
neurofibrillary pathology (Zhu et al., 2000). It was demonstrated,
both in vitro and in vivo, that the major consequence of Aβ-
induced OS is the activation of p38 that further leads to tau
hyperphosphorylation. This finding is also important as it links
Aβ and tau pathology (Giraldo et al., 2014). Furthermore, in
primary cortical neurons, Aβ-induced OS upregulated levels of
a regulator of calcineurin (RCAN1; which inhibits the activity
of the Ser/Thr tau phosphatase calcineurin), but also increased
levels of GSK-3β and tau phosphorylation (Lloret et al., 2011).
Similarly, neurons from RCAN1−/− mice were more resistant to
various oxidative challenges (Porta et al., 2007).
PP2A is the primary tau phosphatase in the brain and its
activity is suppressed in the brain of AD patients (Taleski and
Sontag, 2018). Inactivation of PP2A, together with the activation
of GSK-3β and increased levels of malondialdehyde, an indicator
of lipid peroxidation, were observed in hypoxia-induced tau
phosphorylation in the rat hippocampus (Zhang et al., 2014a).
Also, neuronal protein peptidyl-prolyl isomerase (Pin1) that
stimulates tau dephosphorylation was found downregulated and
oxidatively modified, and exhibited reduced activity in the AD
hippocampus (Sultana et al., 2006). By changing cis to trans
conformation of the peptide bond and vice versa, Pin1 may cause
significant structural modifications and affect the development
of tau pathology (Sultana et al., 2006; Kimura et al., 2013).
Interestingly, in cultured cortical neurons obtained from a
transgenic rat model that expresses a human truncated tau
protein analogous to a variant form derived from sporadic AD,
the expression of a human truncated tau protein depleted the
number of mitochondria and increased levels of ROS, making
neuronal cells more sensitive to various OS inducers. The authors
suggested that tau truncation precedes OS in the AD and that
OS could be the consequence, rather than the trigger, of tau
pathology in AD (Cente et al., 2006).
OS-related factors that contribute to abnormal tau
hyperphosphorylation also disturb mitochondrial distribution
and induce mitochondrial dysfunction, mitochondrial OS,
and deficiency of antioxidant enzymes such as mitochondrial
superoxide dismutase (Melov et al., 2007; Cheng and Bai,
2018). Mitochondrial deficits in turn facilitate the generation of
oxidants and create a more severe oxidative environment
(Prentice et al., 2015). The induced OS also increases
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FIGURE 2 | Role of tau hyperphosphorylation and oxidation in tau aggregation. Oxidative stress (OS) activates Alzheimer’s disease (AD)-related kinases (GSK-3β,
cdk5, and p38) and inhibits tau dephosphorylation by PP2A, leading to tau hyperphosphorylation. OS-mediated lipid peroxidation results in toxic aldehydes that
further activate tau kinases and trigger conformational changes of hyperphosphorylated tau promoting aggregation.
mitochondrial susceptibility to various stressors, including Aβ
(Pérez et al., 2018), whereas Aβ enhances the production of ROS,
induces lipid peroxidation, disturbs redox balance, and leads to
mitochondrial dysfunction (Diana et al., 2008; Hu and Li, 2016).
Hence, a better understanding of the inducers and consequences
of oxidative damage on tau and neuronal functions, and the
interplay between oxidative environment and tau oxidation and
hyperphosphorylation in AD progression may be important
for future directions in the development of novel therapeutic
options based on antioxidative agents. Although outcomes of
antioxidative therapy are still inconsistent, the appearance of OS
early in the disease progression suggests that antioxidative agents
could be efficient disease-modifying options.
COPPER AS AN OS-INDUCER IN AD
Increase in OS could be generated through the deregulation of
metal homeostasis (Sayre et al., 2000), and there is evidence that
metal-induced OS promotes Aβ deposition and tau pathology
in AD (Greenough et al., 2013; Birla et al., 2020; Wang
et al., 2020). At least partially, OS in AD has been linked
to the impairment of copper homeostasis. Copper is an
essential metal for the maintenance of brain function. It is
an integral part of various enzymes and structural proteins
with many important biochemical and physiological roles
(Stern et al., 2007). It is required for myelin formation and
preservation, the activity of cytochrome c oxidase in cellular
respiration, proper functioning of the superoxide scavenging
enzyme copper/zinc superoxide dismutase (Cu,Zn-SOD), and
catecholamine biosynthesis (Gaetke et al., 2014). On the other
hand, copper is a highly reactive transition metal that participates
in electron-transfer reactions inside the cell. When copper is not
bound, transitions between oxidized (cupric, Cu2+) and reduced
(cuprous, Cu+) states may initiate redox cycling and formation
of dangerous ROS. In physiological conditions concentrations
of copper are very tightly regulated (Gaetke et al., 2014). Many
mechanisms related to uptake, intracellular trafficking, protein
binding, and disposal are engaged to ensure adequate copper
supply to target proteins and keep copper ions in a bound form,
preventing redox reactions and ROS formation. About 95% of
copper from human plasma is bound to ceruloplasmin, and the
rest to albumin, amino acids, and some complexes that may cross
the blood-brain barrier (Squitti et al., 2008; Šimi ć et al., 2019).
Accordingly, cytoplasmic concentrations of unbound copper
are very low (Rae et al., 1999; Kaplan and Lutsenko, 2009;
Gaetke et al., 2014). However, due to many reasons (such as
environmental pollution, excess dietary intake, inborn errors of
copper metabolism and some specific medical conditions), high
amounts of copper may overwhelm the endogenous capacity
of copper-binding and promote OS conditions (Jomova and
Valko, 2011; Eskici and Axelsen, 2012; Gaetke et al., 2014;
Hsu et al., 2018).
In general, monovalent copper is more abundant in healthy
neurons where it occurs at very low concentrations, whereas
levels of Cu2+ are elevated in pathological conditions and
greatly contribute to its toxic effects (Bagheri et al., 2018:
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Kardos et al., 2018; Ahmadi et al., 2019). In the presence of
endogenous antioxidants (such as glutathione and ascorbate),
Cu2+ may be reduced to Cu+. Cuprous ions further initiate
the formation of hydroxyl radicals through the decomposition
of hydrogen peroxide (Fenton reaction). Hydroxyl radicals
generated through this prooxidant reaction can form protein
radicals in a reaction with amino-bearing carbons, and
lipid radicals by attacking unsaturated fatty acids. Moreover,
peroxynitrite formed in the reaction between superoxide
and nitric oxide promotes the release of copper ions from
protein complexes enabling the generation of more ROS
(Zielonka et al., 2010). Hence, ROS and RNS ultimately
induce protein oxidation, peroxidative damage of neuronal
membranes, and DNA damage, promoting the development
of the disease (Gaetke et al., 2014). Also, the interaction
between Cu2+ ions and GSH may result in the disulfide
bond formation and reduction of Cu2+ to Cu+. Although
generated Cu+ may bind to GSH, the formation of Cu(I)-
[GSH]2 complex generates superoxide anions by reducing
molecular oxygen (Speisky et al., 2009). Taken together,
excess levels of copper may exert neurotoxic effects and
jeopardize neuronal functioning and viability by inducing OS
conditions (Reddy et al., 2008; Jazvinšs ćak Jembrek et al., 2014;
Sebio et al., 2019).
COPPER DYSHOMEOSTASIS IN AD
The level of copper in AD is somehow controversial as both
copper deficiency and copper overload were observed when
analyzing serum, plasma, cerebrospinal fluid, and samples from
AD brain regions (Ventriglia et al., 2012; Pu et al., 2017;
Xu et al., 2017; Bagheri et al., 2018; Wang et al., 2020). For
example, Pu et al. (2017) have found elevated levels of serum
copper in patients with moderate and severe AD. On the
contrary, post-mortem levels of copper analyzed by inductively
coupled plasma mass spectrometry (ICP-MS) were reduced
in all AD brain regions examined, including the entorhinal
cortex and hippocampus (Xu et al., 2017). Furthermore,
increased concentration of free copper, i.e., copper not bound to
ceruloplasmin, together with ceruloplasmin fragmentation was
observed in AD patients in a good correlation with pathological
changes and functional impairment (Squitti et al., 2008). A
recent meta-analysis studies revealed that total copper and
unbound copper are elevated in the serum/plasma of AD
patients but decreased in the brain of AD patients (Bagheri
et al., 2018). Taken together, it seems that the aberrant
copper homeostasis could be contributing significantly to AD
pathology. Large population studies further revealed that levels
of copper are negatively correlated with cognitive decline,
subjects with lower blood copper have better short-term and
long-term memory, and incidence of AD is higher in geographic
areas with increased copper environmental concentrations
(Squitti et al., 2016).
Copper ions are transported only in their monovalent
(reduced) state (Macreadie, 2008). However, the imbalance
of copper homeostasis changes properties of copper-binding,
shifting tightly bound copper to copper being almost free in the
cytoplasm. Hence, it has been suggested that decrease in the level
of copper bound to proteins and increase of a loosely bound
copper or free copper could explain increased copper levels
observed in serum and plasma of AD patients (Squitti et al., 2008;
Ventriglia et al., 2012; Bagheri et al., 2018). As specific genes
participating in copper metabolism are also associated with AD
development, copper dysmetabolism and the resulting increase
of labile copper in affected brain areas in AD could be the most
relevant factor when considering the copper contribution to AD
pathological processes (James et al., 2012; Squitti et al., 2016;
Bagheri et al., 2018).
In addition to copper dyshomeostasis, perturbations of the
metabolism of other metal ions, including aluminum, zinc, and
iron, have been reported in AD (Hegde et al., 2009; Kanti
Das et al., 2015; Rana and Sharma, 2019; Wang et al., 2020).
When compared to Al3+, Zn2+, and Fe3+, tau has the highest
binding affinity for Cu2+ (Rane et al., 2020). Although all these
metal ions are capable of oxygen-transfer that results in ROS
generation, copper and iron are particularly efficient as ROS-
catalysts. However, iron is present in a relatively low amount in
the cerebral cortex, and its interactions with Aβ are considered
unlikely. On the other hand, the reasons to focus on copper are
the facts that copper is enriched in the hippocampus, Aβ-copper
complexes are an important source of ROS and OS in AD, and
copper is a cofactor of many enzymes essential for brain function
(Kanti Das et al., 2015; Esmieu et al., 2019; Wang et al., 2020).
Hence, deciphering the role of copper in AD progression, as well
as better understanding of copper-mediated pathological events,
will be beneficial in the context of developing novel therapeutic
approaches for AD.
INTERACTIONS BETWEEN TAU AND
COPPER—IMPACT ON TAU
AGGREGATION
Various models of toxicity suggest that the gain-of-toxic function
of Aβ following Cu2+ binding is one of the most important
mechanisms of copper toxicity in AD. Copper removal attenuates
aggregation of Aβ in vitro, promotes degradation of Aβ deposits,
and prevents ROS production that is induced by the presence of
Aβ/Cu2+ complex (Bagheri et al., 2018). The role of copper in tau
aggregation and tau-mediated toxicity is not well understood. As
explained before, pseudorepeats from the microtubule-binding
domain have an essential role in tau aggregation, but they are
also capable of copper coordination. Hence, it was suggested that
copper could be involved in tau aggregation. There is evidence
that copper promotes tau aggregation (von Bergen et al., 2000;
Soragni et al., 2008; Kitazawa et al., 2009; Kim et al., 2018), and
increased amounts of copper have been detected in NFTs (Sayre
et al., 2000). In a double transgenic mouse model expressing
wild-type human tau, exposure to high amounts of copper has
increased tau hyperphosphorylation and accumulation in the
absence of Aβ, together with the impairment of spatial learning
and memory (Voss et al., 2014). Hence, this study demonstrates
that an increase in tau phosphorylation is not dependent on the
presence of Aβ pathology and emphasizes that targeting copper
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levels could be a beneficial strategy in modifying the progression
of tau pathology.
Tau possesses one or more binding sites for copper, but
binding affinity is not as strong as usually seen for other
metalloproteins. The coordination environment allows for
interactions with intracellular oxidants and reductants, and these
interactions may locally increase the concentration of copper
(Sayre et al., 2000). Copper coordination complexes are capable
to act as inducers of catalytic redox activity in NFTs. It was
shown that copper may catalyze H2O2-dependent oxidation of
a reducing substrate at NFTs (Sayre et al., 2000). Furthermore, a
fragment of tau protein, an octadecapeptide from the R2 unit,
may reduce copper and generate H2O2 and very likely some
other ROS moieties as well. During Cu2+ reduction, R2 is
oxidized and forms dimers linked by a disulfide bond (Su et al.,
2007). As explained above, these dimers are considered to be
building blocks of PHFs. Interestingly, iron, another redox-active
metal ion, does not catalyze tau oxidation (Su et al., 2007).
This finding demonstrates that tau with inappropriately bound
copper may initiate ROS formation and OS conditions. More
importantly, by catalyzing tau oxidation and dimer formation
after conformational tau transition, copper may promote PHF
assembly and disease progression (Su et al., 2007).
COPPER BINDING TO R1-R4 REPEAT
UNITS FROM THE
MICROTUBULE-BINDING DOMAIN
The interactions between copper and individual R1-R4 repeat
units or their smaller fragments involve direct binding of
copper to tau-derived peptides suggesting that copper binding
can induce conformational changes of the microtubule-binding
domain (Ma et al., 2005; Zhou et al., 2007). In the presence
of divalent copper, an increase in α-helix structure content
and β-sheets represents a common spatial change. In R2 and
R3 repeats other conformational and structural changes that
precede, and further trigger the process of aggregation, have
been observed as well. All four pseudorepeats formed aggregates
after 3 days of incubation with Cu2+ solution. Amorphous
aggregates were observed with R1 and R4 repeats, whereas
Cu2+ promoted the formation of fibrils with R2 and R3 repeat
units (Figure 3A). After 4 days of incubation, R2 fibrils
and R3 protofibrils were formed. Furthermore, for R2 repeats
production of ROS was pronounced, whereas R3 repeats were
more prone to aggregation. The oligomerization was also
observed after incubation with hydrogen peroxide, but the
aggregation was more prominent in the presence of Cu2+ and
was not prevented by high amounts of ascorbate, an endogenous
antioxidant (Ahmadi et al., 2019). In the same study, glutathione,
another important antioxidant from neuronal cells, did not
prevent aggregation of pseudorepeats from microtubule-binding
domains under limited access to oxygen. When repeat units were
incubated with Cu2+ and GSH under ambient oxygen, more
and larger protofibrils were formed for R3, which indicates an
important role of GSH in R3 aggregation when Cu2+ is present
(Ahmadi et al., 2019). Taken together, these findings demonstrate
that the Cu2+-induced conformational changes and folds in
tertiary structure may be viewed as a seed for dimerization and
fibril formation afterward.
Shin and Saxena (2011) analyzed Cu(II) coordination of
each of the octadecapeptides from the R1–R4 pseudorepeats.
They suggested a square-planar Cu(II)-coordination geometry
with three nitrogen donors and one oxygen donor. Carbonyl
oxygen of a backbone amide and a nitrogen atom of the
histidine imidazole ring probably directly participate in Cu(II)
coordination in octadecapeptide fragments derived from all
four repeat units (Shin and Saxena, 2011). Other studies
also suggested that octadecapeptides may bind copper and
emphasized the critical role of the histidine imidazole group
in Cu(II) coordination (Ma et al., 2005; Zhou et al., 2007;
Ahmadi et al., 2019). Of note, it seems that residues involved
in interactions between microtubules and tau are not involved
in copper binding. This suggests that copper can bind to
microtubule-bound tau and affect the secondary structure of
many tau molecules (Soragni et al., 2008).
As several studies indicate the important role of the R3 repeat
on tau aggregation, smaller peptide sequences derived from the
R3 unit were of particular interest when considering the effect
of copper on tau aggregation (Ma et al., 2005). At least for
the octadecapeptide 318VTSKCGSLGNIHHKPGGG335 derived
from the R3 repeat of the longest tau isoform, copper-binding
is very strong and of high affinity. In the study of Ma et al.
(2005), imidazole rings of the two histidine residues from this
octadecapeptide are critically involved in Cu2+ coordination,
whereas no evidence was found that backbone amide or side
chains of other amino acids participate in copper coordination
at physiological pH. They suggested that octadecapeptide from
the R3 repeat coordinates Cu2+ via the two imidazole rings of
histidine residues, C-terminal carboxylic group, and N-terminal
amino group in a square-planar geometry (Ma et al., 2005).
Various factors may affect binding properties of copper to
peptides derived from the R3 repeat. For the tau318–335 peptide,
coordinating ligands and conformation are highly dependent on
pH. At acidic pH, confirmation of the main chain in aqueous
solution adopted a mixture of random structure, α-helices, and
β-turns, whereas at physiological pH content of α-helices was
increased (Ma et al., 2005). After adding 0.25 mol eq of Cu2+,
the R3 peptide showed a monomeric α-helical structure, and
the β-sheet was present after adding 1 mol eq of Cu2+ (Ma
et al., 2005). It is commonly accepted that the β-sheet structure
is essential for aberrant protein aggregation. However, α-helices
also may trigger the formation of protein aggregates, and in
addition to the β-sheet structure, α-helices are also found in
PHFs, even though helix-breaking amino acids are abundant in
tau protein (Sadqi et al., 2002). Therefore, these results suggest
that the R3-derived 18-mer can initiate self-aggregation in the
presence of very low concentrations of Cu2+. As α-helices and
β-sheet turns are required for PHF formation, copper is likely
involved in both the initial steps of self-assembly and formation
of PHF-like structures afterward at later stages (Ma et al., 2005).
Because R2 repeat can also form filamentous polymers,
copper-binding properties of the octadecapeptide
287VQSKCGSKDNIKHVPGGG304 from the R2 were also
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FIGURE 3 | Catalytic role of Cu2+ in disulfide bond formation and dimerization. (A) In vitro aggregation of tau fragments derived from the R2 and R3 repeat units
demonstrates the ability of copper to stimulate the formation of PHF-like fibrils. Aggregation is promoted in OS conditions. (B) Dimerization via disulfide bond
formation between Cys residues is the critical initiating step that triggers tau oligomerization and further formation of fibrillar forms. Concomitantly, Cu2+ is reduced to
Cu+, which catalyzes Fenton reaction and production of hydroxyl radicals. The ROS generated induces additional oxidative damage of tau protein promoting
its polymerization.
examined. The 18-mer derived from the R2 repeat binds
copper with 1:1 stoichiometry and low affinity. At physiological
pH, cysteine and the imidazole group of histidine are critical
for copper coordination independent of the main chain.
Cu2+ triggered the formation of α-helices in R2 fragment,
and with increasing copper concentration, more α-helices
were formed. The R2 peptide had a higher ability to form
α-helices compared to the R3 peptide but aggregated at higher
concentrations of copper (Ma et al., 2006). Similarly, peptide
256VKSKIGSTENLKHQPGGG273 from the R1 repeat may bind
copper with 1:1 stoichiometry. The histidine residue is the main
anchor for copper, but only minor changes in the secondary
structure are induced upon copper-binding (Zhou et al., 2007).
Interestingly, the aggregation of the octadecapeptide from the
R1 repeat was inhibited in the presence of copper indicating
that copper binding also could have an inhibitory effect on
aggregation (Zhou et al., 2007). It is assumed that copper-
stimulated aggregation of the R3 peptide could be dependent on
the number of histidine residues in the sequence. Whereas the
R3 peptide contains two histidine residues, only one is present in
R1 (Ma et al., 2005; Zhou et al., 2007). Cu2+-induced structural
changes in Cu-R4 complex were smaller in comparison to the
Cu-R1 complex (Ahmadi et al., 2019). Ahmadi et al. (2019) have
observed that both R1 and R4 repeats form adducts with one or
two copper ions but found no evidence for copper complexation
with R2 and R3 monomers. Instead, their results suggested that
only R2 and R3 dimers form complexes with copper, indicating
an important role of dimerization on Cu2+ complexation.
In R1 and R4 repeats, it seems that Cu2+ interacts with the
imidazole group of histidine, but dimerization was not observed
probably because these repeats do not contain cysteine in their
primary sequence. In cysteine-containing R2 and R3 repeats,
histidine was involved in the interaction, but Cys residues were
probably more involved in aggregation because in presence of
Cu2+ their thiol groups were prone to disulfide bond formation.
It is particularly interesting that the interactions of R2 and
R3 repeats with Cu2+ resulted ROS generation (Ahmadi et al.,
2019). Due to the redox activity of Cu2+, a disulfide bond is
formed between the thiol groups of Cys residues (Figure 3B).
This redox reaction also generates Cu+ ions that further catalyze
ROS production via Fenton-type reactions (Ahmadi et al.,
2019). Another study showed that Cu(II)-2His complex binds to
cysteine, and during cysteine oxidation, a Cu(I)-2His complex
is formed. Similarly, this complex promoted Fenton chemistry
and an increase in ROS production. In a vicious cycle, the
Cu(II)-2His complex was regenerated and was again capable
to oxidize cysteine (Ząbek-Adamska et al., 2013). For R1 and
R4 pseudorepeats, neither oligomerization nor ROS production
was noticed (Ahmadi et al., 2019). The disulfide bond formation
also may be initiated in the presence of hydrogen peroxide.
However, the dimerization of R2 and R3 was more prominent
in the presence of Cu2+ (Ahmadi et al., 2019). After examining
the ability of ascorbate to reduce Cu2+ in the presence of all
repeat units (R1–R4), it was found that R2 and R3 have a higher
affinity for Cu2+ than ascorbate, implying that ascorbate cannot
prevent R2 and R3 dimerization. Taken together, these findings
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suggest an important catalytic role of Cu2+ in oligomerization via
disulfide bond formation and in ROS generation when R2 and
R3 repeats are engaged in copper coordination.
COPPER BINDING TO LARGER TAU
FRAGMENTS
With regards to larger tau fragments, like the 198-residue
K32 fragment that contains the four pseudorepeat motifs and
the two flanking domains from the human tau, it was observed
that in oxidative conditions, peptides 287VQSKCGS293 and
310YKPVDLSKVTSKCGS324 from K32 C-terminal participate
in Cu(II) coordination. To a smaller degree, a tetrapeptide
306VQIV309, and several histidine residues (H299, H329, H330,
H374, H388) were also involved in the interaction (Soragni
et al., 2008). For the K32 fragment, only a small amount of
aggregates were formed following copper binding due to the very
slow rate of aggregation in physiological conditions, although
a propensity toward β-structure was observed upon copper-
binding (Soragni et al., 2008). For both full-length tau and
K32 fragment, Soragni et al. (2008) found only one binding site
for Cu2+ per monomer, with critical residues mainly located in
repeats R2 and R3. It seems that copper simultaneously binds
to R2 and R3 repeats, bringing reactive groups into spatial
proximity. Within R2 and R3 sequences, two cysteine residues
(C291 and C322) are identified as essential for the binding of
copper to tau. Given the copper-induced oxidation of these
cysteines, the intramolecular disulfide bridge between their thiol
groups is probably formed as a result of copper:tau interactions
(Soragni et al., 2008). Hence, this study demonstrates copper-
promoting effects on tau aggregation confirming the important
role of cysteine residues from the R2 and R3 repeats in the process
of oligomerization.
Copper coordination was also examined with peptides derived
from the N-terminal part of tau, outside the microtubule-binding
domain. Two tau fragments, containing residues 1–25 or 26–44,
can anchor copper via two putative binding sites, the imidazole
side chain of the histidine residue or the N-terminal amino
group of the peptide chain. Conformations of both peptides were
changed after the formation of Cu(II) complexes. Interestingly,
both peptide fragments inhibited Cu(II)-mediated aggregation
of Aβ, and the effect was more pronounced for tau26–44 (Di
Natale et al., 2018). Fragments of tau protein originating from the
N-terminus, including tau26–44 peptide, are detected in CSF and
brain tissue from the AD patients (Barthélemy et al., 2016; Zhou
et al., 2018). Fragment tau26–44 in physiological conditions
is not prone to aggregation due to intrinsically disordered
structure, but it represents the minimal amino acid sequence
capable of inducing NMDA receptor-mediated neuronal death
(Amadoro et al., 2006). Chronic exposure of neuronal cultures
to tau26–44 fragment resulted in many features characteristic
of presymptomatic stages of AD pathology such as neuritic
dystrophy, breakdown of microtubules, loss of mitochondria and
impairment of oxidative phosphorylation, indicating that the
extracellularly secreted N-terminal truncated tau fragments may
largely contribute to the development of AD pathology (Atlante
et al., 2008; Florenzano et al., 2017).
The effects of copper were also studied in animal models
that mimic tau pathology (Sedjahtera et al., 2018; Ishihara et al.,
2019). For example, in 3XTg-AD mice, chronic exposure to
copper in drinking water exacerbates tau hyperphosphorylation
and upregulates cdk5 activator p25, whereas the activity of
GSK-3β remains stable. Hyperphosphorylation of tau was
detected at Ser396/Ser404 (PHF-1) epitope, indicating the
presence of late-stage pathological tau and tangle formation
(Kitazawa et al., 2009).
The impact of tau acetylation on tau’s ability to bind copper
ions and the effect of copper ions on the aggregation of
acetylated tau is largely unknown. It was recently shown that the
acetyl mimicking mutation K274Q (lysine mutated to glutamine)
enhances the binding affinity for Cu2+, and Cu2+ ions more
strongly promote aggregation of K274Q when compared to
normal tau (Rane et al., 2020). This suggests that acetylation
additionally increases Cu-induced toxicity and contributes to
neuropathological processes (Rane et al., 2020). The effect of
copper on tau glycosylation yet needs to be determined. For some
proteins, it has been shown that their glycated forms are more
prone to copper-mediated oxidation (Kobayashi et al., 1995), at
least in part via a mechanism that involves the production of
free radicals and protein cross-linking (Chace et al., 1991). Based
on these findings, it could be expected that copper will also be
capable of promoting aggregation of glycosylated tau forms.
Finally, the specific contribution of copper in glial tauopathy
remains to be determined. OS-related markers have been
observed in tauopathy of glial cells (Kahlson and Colodner,
2016), and toxic insult that increases the production of ROS
results in tau cleavage and formation of NFTs in C6 rat
astroglioma cell line (Means et al., 2017). Further studies are
needed to examine the effects of copper deregulation on glial
tauopathy. Based on the important neuron-supportive role of
glial cells, a better understanding of the OS-driven mechanisms
involved in glial tau aggregation could be critical for the
identification of novel targets for effective therapies in AD and
other tauopathies.
TARGETING COPPER LEVELS AS A
POTENTIAL THERAPEUTIC APPROACH
IN AD
Overall these findings indicate that natural or synthetic
copper chelators could be considered as potential therapeutic
agents in AD. In general, metal-targeted therapy is aimed
at metal removal or redistribution. Chelators are intended to
disrupt interactions with metal ions and specific molecules,
ultimately promoting their excretion and preventing detrimental
consequences (Esmieu et al., 2019). However, chelation therapy
has achieved controversial clinical results. For effective and
safe prolonged chelation therapy, the time of application
and dosage of chelating agents must be carefully optimized
(Hegde et al., 2009). The selectivity of metal chelation is also
essential due to the risk of general metal depletion and
interference with metal balance. As an increase in divalent
cations is characteristic for the early phase of AD, potential
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copper chelators are expected to be beneficial only for patients in
the early phase of the disease. Taken together, the development
of safe copper chelators intended for prolonged use, and directed
exclusively to the removal of copper-containing deposits in AD,
is very challenging. Nevertheless, targeting copper levels still
represents a promising option in AD, particularly considering
that increased levels of loosely bound copper are a characteristic
finding in the serum of AD patients (Bucossi et al., 2011).
Considering the multifactorial etiology of AD and numerous
mechanisms contributing to the disease development and
progression, effective therapeutic approach may rely on multi-
target drugs (Sharma et al., 2018). As various factors govern tau
pathology, copper-targeted approaches in alleviating progression
of the disease probably would be more useful if combined
with some other interventions targeting tau pathologies, such
as inhibition of tau kinases, inhibition of post-translational
tau modifications and tau aggregation, active and passive
immunotherapy and modulation of tau degradation processes,
among others. In that regard, the neuroprotective potential
of various polyphenolic compounds, such as flavonoids, has
been evaluated. These dietary antioxidants exert multifunctional
effects, i.e., they act as metal chelators, ROS scavengers, and
modulators of redox signaling (Jazvinšs ćak Jembrek et al., 2012;
Ayaz et al., 2019).
Quercetin is one of the most studied and the most potent
scavengers of ROS (Jazvinšs ćak Jembrek et al., 2012, 2014). It
prevents in vitro fibrillization of recombinant tau protein (2N4R
isoform; Kumar et al., 2019). Molecular dynamic simulations
of the tau fragment containing the R2 domain and the
306VQIVYK311 hexapeptide motif have revealed conformational
changes upon interaction with quercetin. Quercetin interacts
with tau protein in the close vicinity of the most aggregation-
prone region and stabilizes the native random coiled state of the
monomeric tau by specific hydrogen bonding and hydrophobic
interactions (Kumar et al., 2019). Furthermore, quercetin was
effective against okadaic acid-induced tau hyperphosphorylation
in HT22 mouse hippocampal cells by inhibiting cdk5 activity
(Shen et al., 2018). Chelation of quercetin to copper may inhibit
the formation of hydroxyl radicals and exhibit a protective effect
when quercetin is present in excess over copper (Jomova et al.,
2017). However, it should be kept in mind that in the presence
of copper ions quercetin may exhibit both antioxidative and
prooxidative activities, and the outcome of copper/quercetin
interactions is not straightforward (Filipe et al., 2004; Zub či ć
et al., 2020).
Another examined flavonoid is epigallocatechin-3-gallate
(EGCG) from green tea. Oral administration of EGCG in
drinking water in mice with the Swedish APP mutation
suppressed the formation of sarkosyl-soluble phosphorylated
tau isoforms and improved cognitive performance (Rezai-Zadeh
et al., 2008). In rat primary neurons EGCG increased the
clearance of phosphorylated tau species (Chesser et al., 2016) and
inhibited the aggregation of tau fragment His-K18∆K280 into
insoluble, high-molecular-weight oligomers at substoichiometric
concentrations. This fragment spans the microtubule-binding
domain of the longest human tau isoform but lacks Lys280,
and readily adopts β-sheet structures resulting in the formation
of toxic and oligomeric tau aggregates. EGCG may exert its
effects by preventing conformational changes by specifically
interacting with early aggregation intermediates and preventing
their seeding activity (Wobst et al., 2015). EGCG acts as a
ROS scavenger and prevents OS-induced DNA damage and
Aβ-induced lipid peroxidation, and increases the production
of GSH by activating the Nrf2 antioxidant pathway (Ayaz
et al., 2019). Moreover, EGCG may interfere with the Cu(II)-
induced fibrillization and aggregation of α-synuclein, whose
abnormal aggregation is characteristic of Parkinson’s disease and
reduces the generation of Cu(II)-induced production of ROS
(Teng et al., 2019).
Curcumin, an extract from the rhizome of the plant
Curcuma longa, is highly recommended as a health-promoting
polyphenolic nutraceutical. As a multi-target compound, it is also
considered for the prevention and treatment of AD. It readily
crosses the blood-brain barrier, preserves synaptic structure
and functions, and positively affects learning and memory
abilities in AD rats (Reddy et al., 2018). Curcumin has powerful
antioxidant properties. It reduces OS acting as an effective
ROS scavenger, stimulates the activity of superoxide dismutase
and catalase, elevates glutathione level, and decreases lipid
peroxidation (Chen et al., 2018). As a natural β-diketone ligand,
curcumin strongly chelates various metals, including copper.
Accordingly, it is considered that curcumin could be effective
against copper-induced neurotoxicity in AD (Wanninger et al.,
2015). In N2a/APP695swe cells and APP/PS1 transgenic mice
curcumin reduced tau phosphorylation and activity of GSK-3β
(Sun et al., 2017). Similarly, in Tg2576 mice overexpressing Aβ,
the administration of turmeric extract for 6 months reduced
the level of hyperphosphorylated tau by ∼80% (Shytle et al.,
2012). In vitro studies have shown that curcumin binds to
4R0N adult tau, prevents the formation of β-sheet structure and
inhibits tau oligomerization and filamentation, and is capable
to induce disaggregation of the preformed tau oligomers and
fibrils (Rane et al., 2017). Based on these three examples,
it is likely that natural compounds, acting as potent metal
chelators and antioxidants, could be a promising approach
in the prevention and therapy of Cu-related tau pathology.
Consequently, further studies are needed to explore and better
explain the potential beneficial effects of natural polyphenolic
compounds against copper-induced toxicity in animal models
and clinical studies.
Small synthetic ligands acting as copper chelators have
already been designed, primarily to remove copper from Aβ
aggregates. As mentioned previously, chelating molecules must
have some properties. They have to be nontoxic, capable to
cross the blood-brain barrier and bind copper with moderate
affinity. It is also important for chelating agents to chelate
unbound copper ions and sink copper ions from the deposits,
but not to remove metal ions from various metalloproteins
(Sharma et al., 2018). Probably the most studied copper-
chelating agents are clioquinol derivatives that are efficient in
removing metal ions from Aβ and disassembling of preformed
Aβ aggregates. They can improve cognitive functions in a
transgenic animal, but the evidence of their positive effects in
clinical studies is still missing (Budimir, 2011; Sharma et al., 2018;
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Esmieu et al., 2019). Regarding copper complexation and
tau pathology, few studies have been performed. In human
neuroblastoma cells incubated with excess copper for 24 h,
the increase in tau phosphorylation at AD-specific sites was
reduced by a copper complexing agent that decreased expression
of the p35/p25 activators of cdk5 (Voss et al., 2014). In the
same study, oral administration of zinc acetate in drinking
water depleted environmental brain copper levels in male
mice expressing wild-type human tau (hTau strain). Zinc
acetate increased the overall expression of tau protein and
reduced tau phosphorylation at Ser202/Thr205, Thr231, and
Ser396/Ser404 (PHF-1 epitope). Expression of p35/p25 activators
and cdk5 was unchanged, whereas GSK-3β and its inhibited form
phosphorylated at Ser9 were depleted, probably contributing to
decreased tau phosphorylation when copper levels were reduced
(Voss et al., 2014). However, these changes in expression level
and phosphorylation patterns did not improve spatial learning
and memory of 18-months-old hTau animals (Voss et al.,
2014).
In another study, it was shown that benzothiazole-containing
compounds can bind Cu2+ and form complexes with a
prominent free-radical scavenging activity. Theoretically, by
competing with tau for Cu binding, these compounds may
reduce Cu-induced damage in the brain (Geng et al., 2012). Bis(8-
aminoquinoline) ligands are yet another example of specific and
efficient Cu2+ chelators that may remove Cu2+ from amyloids
and attenuate ROS production. In a reduced environment,
they are demetallated and release copper ions that may help
in regaining copper homeostasis under reductive conditions
(Nguyen et al., 2014). Finally, an interesting study was performed
with a GSK-3β inhibitor termed CuII (gtsm). The study indicated
that delivering more copper can indirectly exert a beneficial effect
on tau pathology. CuII (gtsm) is a metal complex that delivers Cu
into cells and increases the intracellular bioavailability of copper.
When exposed to a reducing environment, CuII is reduced to
CuI and dissociates from the ligand, thus increasing levels of
copper inside the cell (Crouch et al., 2009). In SH-SY5Y cells,
CuII (gtsm) inhibited the activity of GSK-3β and decreased tau
phosphorylation at Ser404 and Ser396. By comparing effects of
CuII (gtsm) and negative control, namely, compound CuII (atsm)
that is not prone to reduction and dissociation, it was found that
increased bioavailability achieved by CuII (gtsm) is required for
the reduced activity of GSK-3β (Crouch et al., 2009).
By searching for AD-modifying therapy, a better
understanding of metal dyshomeostasis and the exact potential
of antioxidant/chelating strategies in slowing down tau-related
pathology must be further explored, particularly in preclinical
and clinical studies. Despite some promising findings, the
relevance of targeting copper levels for the improvement
or reversal of pathophysiological changes in AD is still
controversial. Due to aberrant copper homeostasis in AD,
the brain metal redistribution and re-establishing of metal
homeostasis, rather than metal removal, could be considered as
a primary goal of metal targeted strategies (Hegde et al., 2009).
It is crucial for future studies to deduce the protective potential
of copper-based strategies and to better understand the effects of
these potential approaches on the progression of tau pathology.
More pharmacological and toxicological studies are needed to
better understand the pharmacodynamic and pharmacokinetic
properties of these potential copper-modifying agents. In that
regard, the aforementioned natural compounds, applied either
alone or in a combination with some other drugs, could be a
promising approach based on their general safety and the ability
to attenuate several copper-related effects.
CONCLUSION
Deregulation of copper homeostasis promotes an OS
condition that is recognized as an early event in AD.
Copper-tau interactions represent an important molecular
factor contributing to the pathological changes in AD. Recent
findings demonstrate the catalytic role of Cu2+ in aggregation
as it triggers conformational changes of tau peptides located
in the microtubule-binding domain. Cu2+ not only promotes
aggregation but contributes to increased ROS formation,
further promoting OS conditions and neuronal damage. Metal
ion chelators and antioxidants capable to reduce copper-
mediated oxidative injury and propagation of tau aggregation
have been suggested as promising approaches in alleviating
AD progression. Natural polyphenolic compounds have metal-
chelating and antioxidative properties that make them promising
and safe multi-target drug candidates. Paradoxically, there are
reports which suggest that delivering more copper, instead of
less, might be beneficial. Further investigation of the interactions
between tau and copper might help in the development of novel
copper-chelating approaches that hopefully will modify the
progression of the disease after regaining copper homeostasis.
Based on many pathological mechanisms contributing to
AD progression, and taking into consideration that chelating
approaches must be applied with caution as chelators are not
selective and levels of copper and other metals should not be
over-reduced, a combined therapy directed against multiple
processes is expected to yield better efficacy. In that regard,
inhibitors of tau aggregation as well as dissociation agents (such
as immunotherapy), could be applied together with chelators
and antioxidative agents.
AUTHOR CONTRIBUTIONS
MJ wrote the initial draft. KZ contributed to literature collection.
PH and GŠ supervised and edited the manuscript. All authors
contributed to the article and approved the submitted version.
FUNDING
This work was funded by the Croatian Science Foundation
(Hrvatska Zaklada za Znanost) grant IP-2019-04-3584, by
the Scientific Centre of Excellence for Basic, Clinical, and
Translational Neuroscience CORE-NEURO (‘‘Experimental and
clinical research of hypoxic-ischemic damage in perinatal and
adult brain;’’ GA KK01.1.1.01.0007 funded by the European
Union through the European Regional Development Fund),
and in part by National Institutes of Health (NIH) grants
AG005138 and AG066514.
Frontiers in Molecular Neuroscience | www.frontiersin.org 14 September 2020 | Volume 13 | Article 572308
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and Hof, P. R. (2009). Does Alzheimer’s disease begin in the brainstem?
Neuropathol. Appl. Neurobiol. 35, 532–554. doi: 10.1111/j.1365-2990.2009.
01038.x
Smith, M. A., Casadesus, G., Joseph, J. A., and Perry, G. (2002). Amyloid-beta and
tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic.
Biol. Med. 33, 1194–1199. doi: 10.1016/s0891-5849(02)01021-3
Soragni, A., Zambelli, B., Mukrasch, M. D., Biernat, J., Jeganathan, S.,
Griesinger, C., et al. (2008). Structural characterization of binding of Cu(II) to
tau protein. Biochemistry 47, 10841–10851. doi: 10.1021/bi8008856
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Zubčić et al. Copper in Tau-Related Alzheimer’s Pathology
von Bergen, M., Barghorn, S., Li, L., Marx, A., Biernat, J., Mandelkow, E. M.,
et al. (2001). Mutations of tau protein in frontotemporal dementia promote
aggregation of paired helical filaments by enhancing local beta-structure. J. Biol.
Chem. 276, 48165–48174. doi: 10.1074/jbc.m105196200
von Bergen, M., Friedhoff, P., Biernat, J., Heberle, J., Mandelkow, E. M., and
Mandelkow, E. (2000). Assembly of tau protein into Alzheimer paired helical
filaments depends on a local sequence motif ((306)VQIVYK(311)) forming
beta structure. Proc. Natl. Acad. Sci. U S A 97, 5129–5134. doi: 10.1073/pnas.
97.10.5129
Voss, K., Harris, C., Ralle, M., Duffy, M., Murchison, C., and Quinn, J. F.
(2014). Modulation of tau phosphorylation by environmental copper. Transl.
Neurodegener. 3:24. doi: 10.1186/2047-9158-3-24
Wang, J. Z., Grundke-Iqbal, I., and Iqbal, K. (1996). Glycosylation of microtubule-
associated protein tau: an abnormal posttranslational modification in
Alzheimer’s disease. Nat. Med. 2, 871–875. doi: 10.1038/nm0896-871
Wang, Y., and Mandelkow, E. (2016). Tau in physiology and pathology. Nat. Rev.
Neurosci. 17, 5–21. doi: 10.3389/fnana.2016.00044
Wang, L., Yin, Y. L., Liu, X. Z., Shen, P., Zheng, Y. G., Lan, X. R., et al. (2020).
Current understanding of metal ions in the pathogenesis of Alzheimer’s disease.
Transl. Neurodegener. 9:10. doi: 10.1186/s40035-020-00189-z
Wanninger, S., Lorenz, V., Subhan, A., and Edelmann, F. T. (2015).
Metal complexes of curcumin--synthetic strategies, structures and
medicinal applications. Chem. Soc. Rev. 44, 4986–5002. doi: 10.1039/c5cs
00088b
Wille, H., Drewes, G., Biernat, J., Mandelkow, E. M., and Mandelkow, E.
(1992). Alzheimer-like paired helical filaments and antiparallel dimers formed
from microtubule-associated protein tau in vitro. J. Cell Biol. 118, 573–584.
doi: 10.1083/jcb.118.3.573
Wischik, C. M., Harrington, C. R., and Storey, J. M. (2014). Tau-aggregation
inhibitor therapy for Alzheimer’s disease. Biochem. Pharmacol. 88, 529–539.
doi: 10.1016/j.bcp.2013.12.008
Wischik, C. M., Schelter, B. O., Wischik, D. J., Storey, J. M. D., and
Harrington, C. R. (2018). Modeling prion-like processing of tau protein in
Alzheimer’s disease for pharmaceutical development. J. Alzheimers Dis. 62,
1287–1303. doi: 10.3233/jad-170727
Wobst, H. J., Sharma, A., Diamond, M. I., Wanker, E. E., and Bieschke, J. (2015).
The green tea polyphenol (−)-epigallocatechin gallate prevents the aggregation
of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett. 589,
77–83. doi: 10.1016/j.febslet.2014.11.026
Xu, J., Church, S. J., Patassini, S., Begley, P., Waldvogel, H. J., Curtis, M. A., et al.
(2017). Evidence for widespread, severe brain copper deficiency in Alzheimer’s
dementia. Metallomics 9, 1106–1119. doi: 10.1039/c7mt00074j
Yeung, A., Tzvetkov, N. T., Georgieva, M. G., Ognyanov, I. V., Kordos, K.,
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